Lattice Biologics Ltd.
Other OTCTotal Valuation
Lattice Biologics Ltd. carries a market capitalization of 16,545.00, placing it among publicly traded companies globally. Its enterprise value stands at 3.21M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 16,545.00 |
| Enterprise Value | 3.21M |
Share Statistics
Lattice Biologics Ltd. currently has 128.22M shares outstanding.
| Shares Outstanding | 128.22M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.06, and the price-to-book ratio stands at 40.64.
| PE Ratio | N/A |
| PS Ratio | 2.06 |
| PB Ratio | 40.64 |
| P/TBV Ratio | -6.34 |
| P/FCF Ratio | 7.36 |
| P/OCF Ratio | -24.28 |
Enterprise Valuation
On an enterprise value basis, Lattice Biologics Ltd. trades at an EV/EBITDA multiple of 47.53 and an EV/FCF ratio of 3.18.
| EV / Sales | 2.06 |
| EV / EBITDA | 47.53 |
| EV / EBIT | N/A |
| EV / FCF | 3.18 |
Financial Position
| Current Ratio | N/A |
| Quick Ratio | N/A |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -0.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -59.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.83 |
Stock Price Statistics
Lattice Biologics Ltd.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lattice Biologics Ltd. generated 1.56M in revenue and converted that into -923,680.00 in net income, yielding earnings per share of -0.01. EBITDA reached -300,573.00, while operating income came in at -544,233.00.
| Revenue | 1.56M |
| Gross Profit | 444,547.00 |
| Operating Income | -544,233.00 |
| Pretax Income | -923,680.00 |
| Net Income | -923,680.00 |
| EBITDA | -300,573.00 |
| EBIT | -544,233.00 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Total book value stands at 78,881.00, with working capital of -505,685.00 providing operational flexibility.
| Cash & Cash Equivalents | N/A |
| Total Debt | N/A |
| Net Debt | N/A |
| Equity (Book Value) | 78,881.00 |
| Book Value Per Share | 0.00 |
| Working Capital | -505,685.00 |
Cash Flow
Lattice Biologics Ltd. produced -132,009.00 in operating cash flow over the past twelve months. After subtracting -567,789.00 in capital expenditures, free cash flow totaled -699,798.00 - equivalent to -0.01 per share.
| Operating Cash Flow | -132,009.00 |
| Capital Expenditures | -567,789.00 |
| Free Cash Flow | -699,798.00 |
| FCF Per Share | -0.01 |
Margins
Lattice Biologics Ltd. operates with a gross margin of 28.53, reflecting its pricing power and cost economics. The operating margin of -34.93 and net profit margin of -59.29 provide insight into operational efficiency.
| Gross Margin | 28.53 |
| Operating Margin | -34.93 |
| Pretax Margin | -59.29 |
| Profit Margin | -59.29 |
| EBITDA Margin | -19.29 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -23.02 |
| FCF Yield | 13.59 |
Stock Splits
Lattice Biologics Ltd.'s most recent stock split took place on January 4, 2016 with a 3:1 split ratio.
| Last Split Date | 1/4/2016 |
| Split Ratio | 3:1 |
Scores
Lattice Biologics Ltd. posts an Altman Z-Score of -795.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -795.14 |